Lilly PR from Phase 3 trial in high risk, non-hosp

Lilly PR from Phase 3 trial in high risk, non-hospitalized, newly diagnosed Covid:

https://www.prnewswire.com/news-releases/new-...14598.html

Quote:

---

INDIANAPOLIS, Jan. 26, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, "events" in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial, Eli Lilly and Company (NYSE: LLY) announced. Across 1,035 patients, there were 11 events (2.1 percent) in patients taking therapy and 36 events (7.0 percent) in patients taking placebo, representing a 70 percent risk reduction (p= 0.0004). There were 10 deaths total, all of which occurred in patients taking placebo, and no deaths in patients taking bamlanivimab and etesevimab together.

---

100% reduction in deaths.
70% reduction in hospitalizations or death

Need to treat 20 high risk patients with IV neutralizing antibodies to prevent 1 hospitalization or death, and 50 high risk patients with IV to prevent each death.

Have to also hope the neutralizing antibodies from the original SARS2 variant still will work on new SARS2 variants that are now out.